WEDNESDAY, July 16, 2025 (HealthDay News) — In a study published online July 9 in Blood Cancer Discovery, real-world outcomes are described for teclistamab, a T-cell-engaging bispecific antibody that targets multiple myeloma (MM) cells via the B-cell maturation antigen (BCMA) receptor. Beatrice M. Razzo, M.D., from the University of Pennsylvania in Philadelphia, and colleagues conducted […]
The post Many Ineligible for Clinical Trial Could Benefit From Teclistamab for Multiple Myeloma first appeared on Physician’s Weekly.
